Capsugel has announced the broad commercial availability of its proprietary lipid multiparticulate (LMP) technology. Capsugel's LMP technology is a drug-delivery platform with multiple applications, including bioavailability enhancement, taste-masking and modified release, for both pharmaceutical and health and nutrition (H&N) products. The company's LMP technology is based on the company’s melt-spray congeal (MSC) processing and combines lipid-based formulations (LBF) with the functionality of a multiparticulate dosage form in one  offering.

MSC processing for LMP production is currently available at Capsugel's manufacturing site in Bend, Oregon., and a commercial-scale facility with MSC processing and capsule-filling capability was recently installed at its location in Greenwood, South Carolina. The company is also continuing to innovate and evolve its global manufacturing processes and capabilities for LMP to extend the reach and applicability for its global customer base.

Source: Capsugel